IRIS
NOBBIO, LUCILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.739
AS - Asia 19
SA - Sud America 3
NA - Nord America 1
Totale 7.762
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.739
CN - Cina 16
BR - Brasile 3
SG - Singapore 2
HK - Hong Kong 1
US - Stati Uniti d'America 1
Totale 7.762
Salva come PNG Salva come JPEG
Città #
Genova 4.255
Genoa 2.152
Rapallo 762
Vado Ligure 553
Bordighera 17
Beijing 6
Singapore 2
Ashburn 1
Guarulhos 1
Hong Kong 1
Porto Alegre 1
São José dos Campos 1
Totale 7.752
Salva come PNG Salva come JPEG
Nome #
Experimental Charcot-Marie-Tooth type 1A: A cDNA microarrays analysis 187
Does parkin play a role in the peripheral nervous system? A family report 182
Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. 178
The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A 175
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies 174
Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22 159
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. 159
Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. 159
Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies 157
Hyccin, the Molecule Mutated in the Leukodystrophy Hypomyelination and Congenital Cataract (HCC), Is a Neuronal Protein. 154
Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations 152
Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth type 1A disease 152
Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy 150
Mitichondrial dysfunction in experimental Charcot-marie-Tooth type 1° (CMTIA) neuropathy: a possible key factor for the axonal degeneration 147
Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. 147
PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. 146
Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy 143
Mifepristone (RU 38486) influences expression of glycoprotein Po and morphological parameters at the level of rat sciatic nerve: In vivo observations . 142
Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients. 138
Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease 138
Inherited Peripheral Neuropathies 135
Correlation among demyelination and axonal degeneration: a new trophic role for myelin sheath 129
Synaptopodin and 4 novel genes identified in primary sensory neurons. 129
A P2X7 antagonist improves muscle strength and motor distal amplitude in CMT1A rats: preliminary results from an in vivo trial 127
P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy 127
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 124
Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 121
Diadenosine homodinucleotide products of ADP-ribosyl cyclases behave as modulators of the purinergic receptor P2X7. 119
Genetic Workup for Charcot–Marie–Tooth Neuropathy: A Retrospective Single-Site Experience Covering 15 Years 119
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol 118
A P2X7 antagonist improves muscle strength and motor distal amplitude in CMT1A rats: preliminary results from an in vivo trial 117
PMP22 messenger RNA levels in skin biopsies: Testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker 117
P2X7 antagonism in experimental CMT1A: a potential therapeutic strategy 117
Oxydative phosphorilation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 116
Tyrosine kinase A-Nerve Growth Factor receptor is antigenically present in dystrophic neurites from a variety of conditions but not in Alzheimer's disease. 116
Ebf Genes In Peripheral Nerve Myelination 114
Role of the P2X7 receptor in the altered calcium homeostasis of Schwann cells overexpressing peripheral myelin protein 22 108
Energetic disfunction in CMT1A: role of myelin and neuron mitochondria 107
Neuroactive Steroid Levels in a transgenic rat model of CMT1A Neuropathy. 107
The transcription factors EBF1 and EBF2 are positive regulators of myelination in Schwann cells 107
The diadenosine homodinucleotide P18 improvesin vitromyelination in experimental Charcot-Marie-Tooth type 1A 105
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 105
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. 102
P2X7 overexpression is responsible for the increased intracellular calcium and functional derangement in Schwann cells from rats with Charcot-Marie-Tooth type 1A neuropathy. 100
Ebf genes' silencing impairs myelin formation 100
Energy supply and demyelinising diseases: a new trophic role of myelin sheath. 99
Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats 99
P2X7 overexpression is responsible for the increased intracellular calcium and functional derangement in Schwann cells from rats with Charcot-Marie-Tooth type 1A neurophaty. 98
A P2X7 antagonist improves muscle strength and motor distal amplitude in CMT1A rats: preliminary results from an in vivo trial. 98
Energetic metabolism of myelinated axons: a new correlation among axonal degeneration, demyelination and energy supply. 96
Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations 95
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1° (CMT1A) neuropathy. 94
P2X7 RECEPTOR IMPLICATION IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 91
P2X7 TARGETING IMPROVES IN VITRO MYELINATION IN EXPERIMENTAL CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 90
Functional Characterization of Hyccin, a Novel Membrane Protein Involved in Central and Peripheral Myelination 88
A novel mouse model of CMT1B identifies hyperglycosylation as a new pathogenetic mechanism 87
The SPTLC1 p.S331 mutation bridges sensory neuropathy and motor neuron disease and has implications for treatment 86
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1° (CMT1A) neuropathy. 81
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. 81
Role of the P2X7 receptor in the altered calcium homeostasis of Schwann cells overexpressing peripheral myelin protein 22 (PMP22) 81
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1° (CMT1A) neuropathy. 77
Neuropatie di Charcot-Marie-Tooth: dalla patologia alla patogenesi 64
DEVELOPMENT AND VALIDATION OF A BIOMARKERS PANEL TO CAPTURE PATHOPHYSIOLOGICAL HETEROGENEITY OF GBS AND CIDP PATIENTS 63
Inherited neuropathies. 63
null 48
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS 41
Guillain barré syndrome of axonal type in a multple sclerosis patient: Fortuitous association or linked disorders? 41
Techniques for the standard histological and ultrastructural assessment of nerve biopsies 25
Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients 17
Basic Pathological Mechanisms in Peripheral Nerve Diseases 9
Increased [18F]DPA-714 Uptake in the Skeletal Muscle of SOD1G93A Mice: A New Potential of Translocator Protein 18 kDa Imaging in Amyotrophic Lateral Sclerosis 7
Rituximab retreatment guided by CD27+ B-cell count vs. clinical relapse in anti-MAG polyneuropathy: a cost-effective approach with lower cumulative doses 5
Totale 7.849
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.191
article - articoli 20.208
book - libri 0
conference - conferenze 5.589
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 394
Totale 52.382
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021250 0 0 0 36 16 25 22 32 32 28 29 30
2021/2022756 16 69 51 86 20 48 44 186 32 63 31 110
2022/2023885 74 82 7 83 173 132 2 81 139 6 94 12
2023/2024494 31 51 15 63 36 85 58 39 22 10 23 61
2024/20251.426 96 83 52 104 167 126 111 272 53 48 154 160
2025/2026718 372 71 133 142 0 0 0 0 0 0 0 0
Totale 7.849